Induction Optimization With Stelara for Crohn's Disease
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a 16-week randomized controlled trial comparing a second IV weight-based induction
dose at week 8 to standard 90mg subcutaneous dose at week 8, with a primary endpoint of
clinical remission at week 16.